Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - Mizuho
May 19, 2021 12:42 PM EDTMizuho Securities analyst Mara Goldstein weighed in on Iovanace Biotherapeutics (NASDAQ: IOVA) after the company announced that Maria Fardis, Ph.D. will resign as President and CEO of the company following today's regulatory setback.
"The commercial potential for lifileucel remains but the question... More
